Hosted on MSN2mon
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
The experimental drug puts semaglutide, the ingredient in Ozempic and the weight-loss drug Wegovy, together with a medicine called cagrilintide to make the combination Novo Nordisk calls CagriSema.
Hosted on MSN2mon
Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
The REDEFINE-1 trial of Novo Nordisk’s new drug showed patients who took CagriSema experienced 22.7% average weight loss after taking the combination of semaglutide and cagrilintide over 68 ...